ASLAN Pharmaceuticals (ASLN)

[keekee]

That shows how awfully stupid some of these people that trade heavy in this market could be. No BRAINS, except the trickery they use in convincing investors to give them money to mlm invest. I am flabbergasted!!!!

[europtiger]

Yeah lol ;)

Let’s make some Profit here now... I just belive the gap has a lil to much gravity

[keekee]

Feeling infinitely powerful that I determine the price action of several stocks just by a comment on Ihub. Amazing how I achieved this...but like Trump will say, I guess I am smart. Lol. Just kidding

[keekee]

These guys selling this are pathetically idiotic in their cluelessness. They've made me tons of money. I have to patent them if I can. I wish!!!

[keekee]

No gap....I played the foolish shorts. Sold a couple of thousands at $2.86 while holding the rest. Then I n posted my first enjoy ride move. I knew they would react. So, now just bought back the stuff I sold at $2.86...at $2.48. The want the play...I have the arrows. LMFAOO again!

[europtiger]

The gap is such a sucker... let’s sucker

[ALERTS100%to10000%GAIN]

smartass not looking good when you are here lol

[europtiger]

Looks like gapfill coming

[europtiger]

Got more 2,68 let’s see

[keekee]

Oh BOY...watch out. LMFAOO. $3.50 here we go!

[europtiger]

Thx ;)

[TheFinalCD]

genießen

https://www.thekitchn.com/recipe-german-gluhwein-238371

[europtiger]

I won’t make to many... going to Christkindl Markt having some Glühwein ;)

[TheFinalCD]

lets see how many posts the jackal makes today



lets count

[ALERTS100%to10000%GAIN]

smartass why you blocked PM,fear?

[keekee]

$3.50 target by Friday

[ALERTS100%to10000%GAIN]

see you smartass

[TheFinalCD]

ok spambot

[ALERTS100%to10000%GAIN]

ok smartass

[TheFinalCD]

I will if you change yours to ROBOT-SPAM-POSTER

[ALERTS100%to10000%GAIN]

prideass definetly change your profile name

[ALERTS100%to10000%GAIN]

got better name smartprideass

[keekee]

Enjoy the ride everyone!

[ALERTS100%to10000%GAIN]

ASLN~~2.84 PM

[europtiger]

Looking strong

I don’t have 40k this time... but still quiet a few ;)

[ALERTS100%to10000%GAIN]

ASLN connection here ProteKt Therapeutics Raises $3.6 Million in Post-incubation Financing
November 13, 2019

ProteKt Therapeutics, a biotech company developing new PKR kinase inhibitor based therapies for neurodegenerative diseases including Alzheimer’s Disease, today announced the signing of a binding agreement for a $ US 3.6 million equity financing round. The financing was co-led by Bukwang Pharmaceutical, Fonds de solidarité FTQ, together with existing investors FutuRx, OrbiMed, Johnson & Johnson Innovation – JJDC, Inc., Takeda Ventures, Inc. and RM Global Partners (RMGP) BioPharma Investment Fund. Proceeds from the financing will be used primarily to select a lead drug candidate molecule and validate its neurotherapeutic effects in vivo. In addition, the company plans to initiate the clinical development of a related diagnostic assay for patient selection and treatment personalization.



“We are happy to welcome new investors Fonds de solidarité Bukwang Pharmaceutical and FTQ, and greatly appreciate the continued support, guidance and assistance of our existing investors,” said Yotam Nisemblat, CEO of ProteKt Therapeutics. “The new funding will enable us to select and validate novel and selective neuroinflammation inhibitors and continue their development all the way to clinical studies with our next financing round. In addition, adopting a precision medicine approach and developing a patient selection diagnostic assay should increase the likelihood for an effective treatment”.



“We are proud to see our portfolio company ProteKt graduate from the FutuRx incubator with the capability to continue its development of novel therapies for unmet medical needs in neurology such as neurodegenerative diseases with the help of new and existing investors,” said Kinneret Savitzky, Ph.D., CEO of FutuRx.



“The Fonds de solidarité FTQ’s investment in ProteKt is our first in the field of neurodegenerative diseases such as Alzheimer’s. We are delighted that ProteKt’s innovative approach will be combined with Québec’s expertise in medicinal chemistry in the fight against this devasting illness,” said Didier Leconte, Vice-President for Investments, Life Sciences and Funds-of-Funds at the Fonds.



“We are impressed with ProteKt’s capability in drug discovery and are delighted to be part of this financing round to move this promising program toward a treatment for neurodegenerative diseases. Bukwang has a strong R&D heritage and this financing round participation further strengthens Bukwang’s portfolio and emphasizes our commitment in the development of novel drugs targets,” said Hee-Won Yoo, Ph.D., CEO of Bukwang Pharmaceutical.



About ProteKt Therapeutics

ProteKt Therapeutics is a drug development company aiming to develop potent and selective oral inhibitors of the kinase PKR for the treatment of neurodegenerative and neuroinflammatory diseases. The company was founded by Carmel, Haifa University Economic Corporation, and the Carmel Innovations Fund based on the research of Prof. Kobi Rosenblum of the Haifa University. ProteKt Therapeutics joined the FutuRx accelerator in 2015, where it has discovered and developed a series of novel and selective molecules by applying unique computational methods and validating the inhibitors in clinically relevant assays.



About the Fonds de solidarité FTQ

The Fonds de solidarité FTQ is a capital development fund that channels the savings of Quebecers into investments. With $15.6 billion in net assets as of May 31, 2019, the Fonds has helped create and protect 215,104 jobs. The Fonds has 3,126 partner companies and today has more than 700,000 shareholders-savers.

[ALERTS100%to10000%GAIN]

ASLN~~~ASLAN PHARMACEUTICALS AND BUKWANG PHARMACEUTICAL ESTABLISH A JOINT VENTURE, JAGUAHR THERAPEUTICS, TO DEVELOP NOVEL IMMUNO-ONCOLOGY THERAPIES
September 30, 2019

ASLAN spins out pre-clinical assets in joint venture with Bukwang to form JAGUAHR Therapeutics with Bukwang investing up to $5million to form JAGUAHR THERAPEUTICS


ASLAN and Bukwang will co-own new entity to develop novel pre-clinical AhR antagonists



– ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, and Bukwang Pharmaceutical (KRX:003000), a leading R&D focused Korean pharmaceutical company, today announced that they have established a new joint venture to develop preclinical aryl hydrocarbon receptor (AhR) antagonists from ASLAN’s early stage pipeline. The independent company, JAGUAHR Therapeutics, will focus on developing new immuno-oncology therapeutics for global markets targeting the AhR pathway and will be based in Singapore.








Under the terms of the agreement, ASLAN will transfer the global rights to all of the assets related to AhR technology, originally discovered and developed by ASLAN and its collaborator Dr Mark Graham, into JAGUAHR. Bukwang will invest US$5 million in JAGUAHR in two tranches to fund the development of the assets, identify a lead development compound and file an Investigational New Drug application.



Dr Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals, said: “The launch of JAGUAHR Therapeutics is an important step by ASLAN to realise the value of our early stage assets and advance the development of our AhR antagonist technology at a time when focus is shifting towards AhR antagonists as a hot new area in immuno-oncology. Bukwang has a strong track record of achievement in the pharma business and creating this spinout together allows both companies to quickly progress these exciting compounds and potentially provide novel clinical assets to enrich the ASLAN pipeline. We look forward to working with the Bukwang team as we focus on identifying JAGUAHR’s first drug candidate.”



Dr Hee-Won Yoo, Chief Executive Officer, Bukwang Pharmaceutical, added: ““We are impressed and delighted to partner with ASLAN to establish JAGUAHR Therapeutics. Bukwang has a strong heritage in R&D and this agreement is aligned to our strategy to strengthen our innovative development pipeline and broaden early access to promising technology for treating conditions with unmet needs. We are very excited as the AhR antagonists program further marks Bukwang’s formal participation in the immuno-oncology arena. We look forward to working together with ASLAN to progress these novel immuno-oncology compounds into clinical development in oncology.”



AhR is a druggable transcription factor that acts as a master regulator of the immune system. The enzymes IDO1, IDO2 and TDO are frequently overexpressed in numerous tumour types and convert tryptophan into kynurenine (KYN) in the tumour microenvironment. KYN is then actively transported into dendritic cells and effector T-cells that are mobilised to detect and kill tumour cells. KYN signalling via AhR in these cell types converts them into regulatory T-cells, suppressing the immune system and preventing it from attacking tumour cells. Research has demonstrated that the unique advantages of AhR antagonists include broadly inhibiting the signalling of all AhR ligands produced by any enzyme that metabolises tryptophan, and robust activation of the immune response to kill cancer cells.

[ALERTS100%to10000%GAIN]

ASLN WOW~~Partners ASLAN is in a joint venture with Bukwang to develop preclinical aryl hydrocarbon receptor (AhR) antagonists. Bukwang Pharmaceutical Co., Ltd. [KRX:003000] was established on 17 October 1960 and has continued to produce and commercialise excellent medications with the aim of improving global health for close to 60 years. Bukwang has a solid business that covers a wide spectrum of indications such as liver, metabolic, CNS and oncology disease. Bukwang’s proven record of its core business provides financial assurance that enables Bukwang to continue pushing into more innovative area of new drug R&D. To learn more about Bukwang, please visit https://www.bukwangpharm.com/

[ALERTS100%to10000%GAIN]

ASLN~~HUGEE~~Our Pipeline
Our portfolio is comprised of one monocloncal antibody therapy targeting inflammatory disease and two small molecule inhibitors targeting oncology.

http://aslanpharma.com/pipeline/

[ALERTS100%to10000%GAIN]

ASLN~~Over the past twenty days of trading, ASLAN Pharmaceuticals Limited (NASDAQ: ASLN), from November 15, 2019 to December 13, 2019 there is a potential Short Squeeze about to happen because of an increase in short volume over the past twenty days with very little cover volume.

Because of this the Squeeze Report trend indicator issued a ASLN Short Squeeze.

[ALERTS100%to10000%GAIN]

ASLN~~HUGE WEBSITE ~~http://aslanpharma.com/

[ALERTS100%to10000%GAIN]

ASLN~~if FDA news tomorrow am will be crazy HUGEEEEEEEEEEEEEEE

[ALERTS100%to10000%GAIN]

bought heavy at 2.31 afternoon

[keekee]

Will rocket tomorrow.

[ALERTS100%to10000%GAIN]

ASLN~~~wow 50k shares left at 2.80 from 105,000 shares,close hod $2.80,wise people loaded today,NEWS am and watch out

[ALERTS100%to10000%GAIN]

ASLN~~2.80 hits now

[ALERTS100%to10000%GAIN]

ASLN $2.72, look at the freaking wowza breaking chart,load up fast

https://www.stockscores.com/charts/charts/?ticker=asln

[ALERTS100%to10000%GAIN]

L2 2.75,2.89,2.98 ,crazy to break ASLN

[TheFinalCD]

[ALERTS100%to10000%GAIN]

2.75 bid above the last price

[ALERTS100%to10000%GAIN]

Crazy buys volume alert

[ALERTS100%to10000%GAIN]

Plenty time till 8:0pm can be above $3.00

[ALERTS100%to10000%GAIN]

87200 left from 105000

[europtiger]

2,80 has now a 80k wall... let’s see

[europtiger]

Very nice... making me sweet money . Agaaaiinn ;)

[ALERTS100%to10000%GAIN]

After $2.80 could break $3.00,crazy run will be tomorrow Asln

[ALERTS100%to10000%GAIN]

Hits at the wall now,94200 shares left

[ALERTS100%to10000%GAIN]

After this 105k shares wall cans be wowza crazy huge run

[ALERTS100%to10000%GAIN]

105k shares wall at 2.80 ,gonna fallout

[ALERTS100%to10000%GAIN]

Get asap in .2.79 hod ,32 %%up Asln